uniQure N.V. (LON:0EE0)
23.20
-0.78 (-3.23%)
Feb 12, 2026, 5:07 PM GMT
uniQure Revenue
uniQure had revenue of $3.70M USD in the quarter ending September 30, 2025, with 61.83% growth. This brings the company's revenue in the last twelve months to $15.75M, down -44.90% year-over-year. In the year 2024, uniQure had annual revenue of $27.12M with 71.17% growth.
Revenue (ttm)
$15.75M
Revenue Growth
-44.90%
P/S Ratio
87.30
Revenue / Employee
$75.36K
Employees
209
Market Cap
1.02B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 27.12M | 11.28M | 71.17% |
| Dec 31, 2023 | 15.84M | -90.64M | -85.12% |
| Dec 31, 2022 | 106.48M | -417.52M | -79.68% |
| Dec 31, 2021 | 524.00M | 486.49M | 1,296.82% |
| Dec 31, 2020 | 37.51M | 30.23M | 415.23% |
| Dec 31, 2019 | 7.28M | -4.00M | -35.48% |
| Dec 31, 2018 | 11.28M | -1.82M | -13.91% |
| Dec 31, 2017 | 13.11M | -11.99M | -47.78% |
| Dec 31, 2016 | 25.10M | 14.86M | 145.24% |
| Dec 31, 2015 | 10.23M | 4.57M | 80.54% |
| Dec 31, 2014 | 5.67M | 1.62M | 40.07% |
| Dec 31, 2013 | 4.05M | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.64B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Spire Healthcare Group | 1.55B |
| CVS Group | 673.20M |
| Genus | 672.80M |
| HUTCHMED (China) | 439.54M |
uniQure News
- 6 days ago - Early uniQure Fabry Trial Shows Lasting Enzyme Boost, Safety Watch - Benzinga
- 6 days ago - Early uniQure Fabry Trial Shows Lasting Enzyme Boost, Safety Watch - Benzinga
- 6 days ago - uniQure (QURE) Shares Promising Data on Gene Therapy for Fabry Disease - GuruFocus
- 6 days ago - uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease - GlobeNewsWire
- 11 days ago - QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - PRNewsWire
- 13 days ago - QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - GlobeNewsWire
- 14 days ago - Alger Small Cap Focus Fund Q4 2025 Portfolio Update - Seeking Alpha
- 15 days ago - QURE Makes Notable Cross Below Critical Moving Average - Nasdaq